About COLCRYS
Tough as ever, but a bit more refined.
With the flare-stopping power of colchicine and a milder side effect profile, COLCRYS brings sophistication to the treatment of gout.
- COLCRYS is the first and only FDA-approved, single-ingredient colchicine product for prophylaxis and the treatment of gout flares1,2
Strong relief that's quick on its feet.
COLCRYS — the ony FDA-approved colchicine product for the treatment of gout flares to demonstrate significant pain relief within 24 hours.1-3
- Significant pain relief was defined as greater than or equal to 50% reduction in pain scores
COLCRYS stops painful gout flares with the proven power of colchicine.2
- COLCRYS demonstrated similar efficacy to high-dose colchicine (38% of patients receiving COLCRYS had a greater than or equal to 50% reduction in pain scores at 24 hours vs 33% of patients receiving high-dose colchicine)
- Given twice daily, 0.6 mg of colchicine, as found in COLCRYS, significantly reduces the frequency of gout flares when used in conjunction with uric acid-lowering therapy
Attack gout with gentle power.
COLCRYS balances the right dose of colchicine with fewer adverse events (AEs) to treat acute gout flares.
Strength and elegance2
- COLCRYS, for prophylaxis of gout flares, is generally well tolerated when paired with uric acid-lowering agents
- The most common adverse event in the prophylaxis of gout was diarrhea
- COLCRYS may be used in patients with mild-to-moderate renal or hepatic impairment
- Close monitoring is recommended for patients with mild-to-moderate renal or hepatic impairment
Elegant therapy. Effortless dosing.
For centuries, dosing colchicine has been inconsistent. Now, with recent data supporting the recommended dosing of COLCRYS, you can prescribe with confidence.2
With the approval of COLCRYS for acute gout flares, dosing is simple: 2 tablets to start followed by 1 tablet 1 hour later.
Dose adjustments2
- No dose adjustment needed for patients with mild-to-moderate renal or hepatic impairment*
- Adjustment recommended for patients with severe impairment (see Prescribing Information)
- Patients with any degree of renal or hepatic impairment should not be given COLCRYS if they are taking a P-gp or strong CYP3A4 inhibitor
- Patients with normal hepatic and renal function require a dose adjustment if they are taking, or have taken in the previous 2 weeks, either P-gp or moderate or strong CYP3A4 inhibitors
*Close monitoring for adverse events of COLCRYS is recommended for these patients.